Vincerx Pharma Inc (VINC)
0.3395
-0.01
(-3.52%)
USD |
NASDAQ |
Nov 12, 16:00
0.3305
-0.01
(-2.65%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.07M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -59.15% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.6521 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform. |
| URL | https://www.vincerx.com |
| Investor Relations URL | https://investors.vincerx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 14, 2024 (est.) |
| Last Earnings Release | Aug. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform. |
| URL | https://www.vincerx.com |
| Investor Relations URL | https://investors.vincerx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 14, 2024 (est.) |
| Last Earnings Release | Aug. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |